Human research · RCT
Denk D et al., Nature Aging 2025
In healthy middle-aged adults, 28 days of oral urolithin A (1,000 mg/day) vs placebo gave a small rise in naive-like CD8+ T cells and higher CD8+ fatty acid oxidation capacity. Other registered primary readouts were null: CD8+ T memory stem cells and SCENITH mitochondrial dependence. These are immune-cell surrogate markers; clinical benefit was not tested.
Source: Effect of the mitophagy inducer urolithin A on age-related immune decline: a randomized, placebo-controlled trial. Denk D, Singh A, Kasler HG, et al. Nature Aging. 2025;5(11):2309-2322. doi:10.1038/s43587-025-00996-x. Trial NCT05735886 (registered 2023-02-21). Correction: doi:10.1038/s43587-025-01060-4
Verified research card EL-20261017-01